Addictive disorders in women

The impact of maternal substance use on the fetus and newborn

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Addictive disorders are rising to epidemic proportions throughout the United States and globally, placing significant social and economic burdens on industrialized societies. It is well-known that a high percentage of drug-dependent individuals are women of childbearing age. Maternal substance use and abuse exposes the fetus to drugs of dependence during critical periods of development, resulting in short- and long-term neurodevelopmental effects in infancy and childhood. Neonatal abstinence syndrome (NAS) is a term thatwas initially used to describe the withdrawal symptoms observed in infants who were exposed to opioids in utero. As we have learned more about the various effects of in utero drug exposure and the subsequent consequences, NAS has become a term that more broadly describes the signs and symptoms of withdrawal resulting from any dependence-inducing substance consumed by a pregnantwoman. The aim of this review is to discuss the perinatal outcome of pregnancy associated with maternal drug use. In the United States and other developed nations, the incidence of NAS continues to rise, paralleling the evolution of the opioid epidemic. Chronic in utero exposures to licit and illicit drugs of dependence have fetal, neonatal, and early childhood consequences and are addressed in this review.

Original languageEnglish (US)
Pages (from-to)e576-e586
JournalNeoReviews
Volume18
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Neonatal Abstinence Syndrome
Substance-Related Disorders
Fetus
Mothers
Newborn Infant
Opioid Analgesics
Pharmaceutical Preparations
Substance Withdrawal Syndrome
Street Drugs
Pregnancy Outcome
Developed Countries
Signs and Symptoms
Economics
Incidence

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

@article{7f56ceb948b44e7db233b17f6f8ca28a,
title = "Addictive disorders in women: The impact of maternal substance use on the fetus and newborn",
abstract = "Addictive disorders are rising to epidemic proportions throughout the United States and globally, placing significant social and economic burdens on industrialized societies. It is well-known that a high percentage of drug-dependent individuals are women of childbearing age. Maternal substance use and abuse exposes the fetus to drugs of dependence during critical periods of development, resulting in short- and long-term neurodevelopmental effects in infancy and childhood. Neonatal abstinence syndrome (NAS) is a term thatwas initially used to describe the withdrawal symptoms observed in infants who were exposed to opioids in utero. As we have learned more about the various effects of in utero drug exposure and the subsequent consequences, NAS has become a term that more broadly describes the signs and symptoms of withdrawal resulting from any dependence-inducing substance consumed by a pregnantwoman. The aim of this review is to discuss the perinatal outcome of pregnancy associated with maternal drug use. In the United States and other developed nations, the incidence of NAS continues to rise, paralleling the evolution of the opioid epidemic. Chronic in utero exposures to licit and illicit drugs of dependence have fetal, neonatal, and early childhood consequences and are addressed in this review.",
author = "Christiana Oji-Mmuo and Tammy Corr and Doheny, {Kim Kopenhaver}",
year = "2017",
month = "10",
day = "1",
doi = "10.1542/neo.18-10-e576",
language = "English (US)",
volume = "18",
pages = "e576--e586",
journal = "NeoReviews",
issn = "1526-9906",
publisher = "American Academy of Pediatrics",
number = "10",

}

Addictive disorders in women : The impact of maternal substance use on the fetus and newborn. / Oji-Mmuo, Christiana; Corr, Tammy; Doheny, Kim Kopenhaver.

In: NeoReviews, Vol. 18, No. 10, 01.10.2017, p. e576-e586.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Addictive disorders in women

T2 - The impact of maternal substance use on the fetus and newborn

AU - Oji-Mmuo, Christiana

AU - Corr, Tammy

AU - Doheny, Kim Kopenhaver

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Addictive disorders are rising to epidemic proportions throughout the United States and globally, placing significant social and economic burdens on industrialized societies. It is well-known that a high percentage of drug-dependent individuals are women of childbearing age. Maternal substance use and abuse exposes the fetus to drugs of dependence during critical periods of development, resulting in short- and long-term neurodevelopmental effects in infancy and childhood. Neonatal abstinence syndrome (NAS) is a term thatwas initially used to describe the withdrawal symptoms observed in infants who were exposed to opioids in utero. As we have learned more about the various effects of in utero drug exposure and the subsequent consequences, NAS has become a term that more broadly describes the signs and symptoms of withdrawal resulting from any dependence-inducing substance consumed by a pregnantwoman. The aim of this review is to discuss the perinatal outcome of pregnancy associated with maternal drug use. In the United States and other developed nations, the incidence of NAS continues to rise, paralleling the evolution of the opioid epidemic. Chronic in utero exposures to licit and illicit drugs of dependence have fetal, neonatal, and early childhood consequences and are addressed in this review.

AB - Addictive disorders are rising to epidemic proportions throughout the United States and globally, placing significant social and economic burdens on industrialized societies. It is well-known that a high percentage of drug-dependent individuals are women of childbearing age. Maternal substance use and abuse exposes the fetus to drugs of dependence during critical periods of development, resulting in short- and long-term neurodevelopmental effects in infancy and childhood. Neonatal abstinence syndrome (NAS) is a term thatwas initially used to describe the withdrawal symptoms observed in infants who were exposed to opioids in utero. As we have learned more about the various effects of in utero drug exposure and the subsequent consequences, NAS has become a term that more broadly describes the signs and symptoms of withdrawal resulting from any dependence-inducing substance consumed by a pregnantwoman. The aim of this review is to discuss the perinatal outcome of pregnancy associated with maternal drug use. In the United States and other developed nations, the incidence of NAS continues to rise, paralleling the evolution of the opioid epidemic. Chronic in utero exposures to licit and illicit drugs of dependence have fetal, neonatal, and early childhood consequences and are addressed in this review.

UR - http://www.scopus.com/inward/record.url?scp=85030693749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030693749&partnerID=8YFLogxK

U2 - 10.1542/neo.18-10-e576

DO - 10.1542/neo.18-10-e576

M3 - Review article

VL - 18

SP - e576-e586

JO - NeoReviews

JF - NeoReviews

SN - 1526-9906

IS - 10

ER -